[{"id":"d6544d5c-22e0-428e-b270-2a60bc0e02bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04447183","created_at":"2021-01-18T21:23:59.877Z","updated_at":"2024-07-02T16:35:32.204Z","phase":"Phase 2","brief_title":"The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.","source_id_and_acronym":"NCT04447183","lead_sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","biomarkers":" TG","pipe":"","alterations":" ","tags":["TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e recombinant human thyroid stimulating hormone for injection (rhTSH)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 11/23/2020","start_date":" 11/23/2020","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-10-23"}]